CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer

Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Cosimo, Serena, Porcu, Luca, Cardoso, Fatima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758367/
https://www.ncbi.nlm.nih.gov/pubmed/33352521
http://dx.doi.org/10.1016/j.breast.2020.12.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758367/
https://www.ncbi.nlm.nih.gov/pubmed/33352521
http://dx.doi.org/10.1016/j.breast.2020.12.006

Ejemplares similares